High doses of hydroxycholorquine did not prevent illness compatible with Coivd-19 when initiated within 4 days after a high risk or moderate risk exposure.



Conclusion of hydroxychloroquine as postexposure prophylaxis

No meaningful difference in effectiveness according to the time of starting the postexpsorue prophylaxis


Santa Clara University

13% of participants were either PCR confirmed or had compatible COVID-19 symptoms that developed during the 14 days follow up. There was not a significant difference between those that received hydroxychloroquine and those that received a placebo. 
P-value of 0.35 and an absolute difference of -2.4 percentage points. 

Patient outcomes of hydroxychloroquine as postexposure prophylaxis

Percent with New COVID-19 cases with hydroxychloroquine as postexposure prophylaxis

For those that took the hydroxychlorquine, 40.1% reported side effects by day 5 compared to 16.8% of the placebo group. Nausea, loose stools, and abdominal discomfort were the most common

Learn Before

Related

Learn After